Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsShroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.
Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.
1.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
2.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
3.
Research team uncovers the underpinnings of head and neck cancers
4.
For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.
5.
Some low-grade prostate cancers carry higher risks than biopsy suggests
1.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
2.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
3.
Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy
4.
Exploring the Role of Fecal Leukocytes in Intestinal Health
5.
Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
4.
Efficient Management of First line ALK-rearranged NSCLC - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge